• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX

PRESCIENT THERAPEUTICS LIMITED

4.26% ! 4.5¢
Market Cap $36.23M  !

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PTX 20:46 53 16K
20:46 Last post  newregime Comments Created with Sketch.  53  Views Created with Sketch.  16K 
PTX
Daily happenings?.
8 9 10
14:02 567 287K
14:02 Last post  Un1qu3Nam3 Comments Created with Sketch.  567  Views Created with Sketch.  287K 
PTX 18/04/25 14 4.4K
Metals & Mining SECTOR NEWS

More Strong Drilling Results for Apollo Hill Gold Project

STN
23 Apr 2025
SATURN METALS LIMITED
18/04/25 Last post  Scotty598 Comments Created with Sketch.  14  Views Created with Sketch.  4.4K 
PTX 16/04/25 8 3.2K
16/04/25 Last post  newregime Comments Created with Sketch.  8  Views Created with Sketch.  3.2K 
PTX 11/04/25 0 407
11/04/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  407 
PTX
Time to stay focused
10/04/25 9 3.9K
10/04/25 Last post  logan123 Comments Created with Sketch.  9  Views Created with Sketch.  3.9K 
PTX 01/04/25 0 377
01/04/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  377 
PTX 31/03/25 8 2.8K
31/03/25 Last post  Shellbell Comments Created with Sketch.  8  Views Created with Sketch.  2.8K 

See All Discussions arrow Created with Sketch.

Timeline

Prescient Therapeutics - Investor Briefing
17 Apr 12:04
 
PTX-100 receives U.S. FDA Fast Track Designation
16 Apr 09:20
 
Initial Director's Interest Notice
11 Apr 09:53
 
PTX appoints Melanie Farris as Non-Executive Director
10 Apr 09:06
 
Final Director's Interest Notice
01 Apr 11:13
 
Prescient Therapeutics - Investor Briefing
31 Mar 09:58
 
View More arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
4.5¢
Change
-0.002(4.26%)
Mkt cap ! $36.23M
Open High Low Value Volume
4.7¢ 4.7¢ 4.5¢ $3.023K 65.69K

Buyers (Bids)

No. Vol. Price($)
2 26147 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.8¢ 100000 1
View Market Depth
Last trade - 16.10pm 23/04/2025 (20 minute delay) ?
Last
4.7¢
  Change
-0.002 ( 6.82 %)
Open High Low Volume
4.6¢ 4.7¢ 4.5¢ 236915
Last updated 15.59pm 23/04/2025 ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.